Antenatal immunoglobulin for prevention of neonatal hemochromatosis. Issue 10 (10th August 2016)

• Record Type: Journal Article
• Authors: Okada, Noriki; Ihara, Yoshiyuki; Urahashi, Taizen; Sanada, Yukihiro; Yamada, Naoya; Hirata, Yuta; Tashiro, Masahisa; Katano, Takumi; Ushijima, Kentaro; Otomo, Shinya; Takahashi, Hironori; Matsubara, Shigeki; Mizuta, Koichi
• Is Part Of: Pediatrics international. Volume 58:Issue 10(2016)
• Page Start: 1059
• Page End: 1061
• Publication Date: 2016-08-10
• Subjects: high‐dose immunogloblin -- neonatal hemochromatosis; Pediatrics -- Periodicals; 618.92
• DOI: 10.1111/ped.13028
• Languages: English
• ISSNs: 1328-8067

Abstract

Abstract: Neonatal hemochromatosis (NH) is a rare disease with a poor prognosis, particularly prior to 2008. Antenatal maternal high‐dose immunoglobulin (Ig) is effective in preventing NH recurrence, but the adverse effects of this treatment have not been documented as yet. Here, we report on a patient who underwent high‐dose Ig treatment to prevent NH recurrence. The patient was a 31‐year‐old pregnant Japanese woman. Her first child died of NH after receiving living donor liver transplantation. The patient received high‐dose Ig treatment to prevent recurrence of NH from gestational weeks 16 to 35. During the treatment, platelet count gradually decreased, and cesarean section was required at 35 gestational weeks. The child did not develop liver failure. High‐dose Ig prevented the recurrence of NH. Caution should be exercised due to possible adverse effects of this treatment.